FDA forces Concert Pharma to hit the brakes on a mid-stage study so it can review tox studies
Concert Pharmaceuticals has been slammed with a clinical hold on a Phase IIa study of its drug CTP-543 for alopecia areata.
The biotech made …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
